Koru Medical price target raised to $4 from $3.50 at Piper Sandler

Piper Sandler raised the firm’s price target on Koru Medical (KRMD) to $4 from $3.50 and keeps a Neutral rating on the shares. The firm notes the company reported Q2 results that beat Street, including revenue of $10.2M/+21% year-over-year as U.S./International grew 15%/34%, respectively. Management also nudged 2025 revenue guidance higher by $1M, reiterated its gross margin percentage outlook, and pointed to positive cash generation in the second half of the year. In general, a solid quarter with upside balanced across the company’s three segments, although Piper would still like to see better translation of the strong top-line growth to P&L leverage.